Johnson & Johnson $JNJ Shares Bought by Retirement Planning Group LLC

Retirement Planning Group LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 203.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,743 shares of the company’s stock after buying an additional 11,888 shares during the period. Retirement Planning Group LLC’s holdings in Johnson & Johnson were worth $3,290,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of JNJ. Evolution Wealth Management Inc. acquired a new position in Johnson & Johnson during the second quarter worth $27,000. Clayton Financial Group LLC purchased a new position in shares of Johnson & Johnson in the third quarter valued at $28,000. Semmax Financial Advisors Inc. raised its stake in shares of Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the last quarter. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter worth about $35,000. Finally, Signature Resources Capital Management LLC increased its holdings in Johnson & Johnson by 262.9% during the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after acquiring an additional 184 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.3%

Shares of Johnson & Johnson stock opened at $218.81 on Friday. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $220.11. The business’s fifty day moving average is $205.82 and its two-hundred day moving average is $186.74. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The firm has a market cap of $527.18 billion, a PE ratio of 21.12, a P/E/G ratio of 2.26 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 14th. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.76 by $0.04. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $23.99 billion during the quarter, compared to analyst estimates of $23.73 billion. During the same period in the prior year, the firm posted $2.42 earnings per share. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on JNJ. Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 22nd. Royal Bank Of Canada set a $240.00 target price on Johnson & Johnson in a research note on Wednesday, December 17th. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. Finally, Johnson Rice set a $190.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $213.33.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.